Ionis wins first FDA approval for Alexander disease. Can Zanvastro make an ultra-rare launch work?
Zanvastro finally gives Alexander disease a targeted therapy. Its next challenge is finding patients and funding a $1.14 million annual regimen.
Pharma & Biotech